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A RETROSPECTIVE ANALYSIS OF SHORT-TERM
COSTS AND UTLIZATION ASSOCIATED WITH
GLYCEMIC CONTROL AMONG TYPE2 DIABETIC
PATIENTS WITHIN A MANAGED CARE
ORGANIZATION
Chen KS, Melikian CA, Chang EY,White TJ
Prescription Solutions, Costa Mesa, CA, USA
Diabetes is the fourth leading cause of death in the U.S.
and a major cause of blindness and heart disease. Studies
have demonstrated that tight glycemic control prevents
long-term microvascular/macrovascular complications
and may offset the associated substantial healthcare costs.
It has been demonstrated that 1.0% or greater improve-
ment in glycemic control resulted in cost saving of
$685–950/patient/year.
OBJECTIVES: To evaluate relationship between total
healthcare costs/utilization and changes in hemoglo-
binA1c (HbA1c) levels as a proxy for aggressive glycemic
control in type2 diabetic patients.
METHODS: A retrospective database analysis of labora-
tory data, pharmacy, and medical claims from a managed
care organization. Patients were selected from a compre-
hensive diabetes management clinic and had at least two
HbA1c tests that were between 3 and 9-months apart. All
patients had at least one oral anti-diabetic medication 
6-months prior to the ﬁrst HbA1c-test. Follow-up time
was time between two HbA1c tests and varied among
patients. Costs and utilization per-member-per-month
were compared between two cohorts, improving glycemic
control and worsening control stratiﬁed by HbA1c
changes (+/-1%). Outcomes were adjusted by age,
gender, co-morbid conditions, insulin-use, previous 
hospitalizations, physician visits, and prescription counts.
RESULTS: A total of 491 patients were identiﬁed, with
mean age of 70.8 (+/-10.5) years, 46.6% female (n =
229), and mean initial-HbA1c-level of 7.2% (+/-1.4; min
= 3.5, max = 13.8). Among them, 45.2% (n = 222) exhib-
ited improved-control and 48.9%(n = 240) exhibited
worsened-control. Patients with improved control had
signiﬁcantly higher adjusted average hospital costs than
those who worsened, $1,374 vs. $449 (p < 0.05).
Although not statistically signiﬁcant, patients with
improved in glycemic control had a higher average
number of anti-diabetic medications and physician visits
than those who worsened.
CONCLUSIONS: Improved glycemic control is associ-
ated with greater short-term healthcare utilization and
costs. Despite relatively well managed by the specialty-
clinic, patients showed further improvement in glycemic
control after hospital events. Future research is needed to
assess the long-term impact of glycemic control on health-
care costs.
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INCIDENCE, MANAGEMENT AND COST OF
CARDIO-VASCULAR AND RENAL
COMPLICATIONS IN FRENCH TYPE 2 DIABETIC
PATIENTS
Fagnani F1, Souchet T2, Labed D3
1CEMKA, Bourg la Reine, France; 2Merck Sharp & Dohme—
Chibret, Paris, France; 3IMS—Health, Nanterre, France
Type 2 diabetes causes a signiﬁcant economic burden on
the healthcare system in developed countries. Manage-
ment of macro and micro vascular complications con-
tributes as a major part of the direct costs.
OBJECTIVE: Estimate the incidence, prevalence, current
management and direct costs of cardiovascular and renal
complications in type 2 diabetic patients in the French
setting.
METHOD: A representative sample of 5,478 diabetic
patients was randomly selected from a database collect-
ing on-line medical data in a network of 650 French GPs.
Patients were selected on the criteria of at least two visits
to their physician on the period May 2000–April 2001.
A questionnaire was sent by mail to the GPs to collect
additional retrospective medical data on renal and cardio-
vascular complications. Corresponding costs were esti-
mated with unit costs from external sources.
RESULTS: The mean duration of diabetes was 10.0 years
and the mean age was 64 years. 29% of patients had a
Hb1c <6.5% and 39.2% in the range 6.5–8%. Annual
incidence of main complications (Myocardial Infarction,
Stroke, Congestive Heart Failure, Chronic Renal Insufﬁ-
ciency and End-Stage Renal Disease) were estimated in
the range 0.54 to 1%. 48% of the patients had BP >
140/80mmHg. The study showed that 26.7% of patients
had no Hb1c testing during the last year, 48% no LDL
cholesterol, 40% no creatininemia and 60% no ophthal-
mologic surveillance. The direct annual costs associated
with these complications were estimated 1 Billion Euros
for the whole French diabetic population (1.5 million).
Contribution to this cost was as following: stroke 36%,
MI 22.2%, CHF 17.4% and ESRD 24.4%.
CONCLUSION: Considering the current glycaemic
control and the quality of management of diabetic
patients, substantial beneﬁts could be achieved that
would reduce the extra-costs of complications.
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HEALTH SERVICES COST AND UTILIZATION
COMPARISONS AMONG LISPRO AND NON-
LISPRO REGULAR INSULIN USERS
Hall JA1, Summers KH2, Obenchain RL2
1Ingenix Pharmaceutical Services, Eden Prairie, MN, USA;
2Eli Lilly & Company, Indianapolis, IN, USA
OBJECTIVE: To compare health services utilization and
cost among commercially insured users of lispro insulin
and non-lispro regular insulin.
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METHODS: This study used administrative claims data
to identify continuously enrolled patients using insulin
between 1/1/98 and 12/31/99. During a six-month iden-
tiﬁcation period, patients receiving one or more prescrip-
tions for lispro were categorized as lispro patients.
Non-lispro patients were then matched to lispro patients
using a Propensity Score (PS) derived from baseline char-
acteristics. The PS model included variables such as age,
gender, comorbidities, oral hypoglycemic use, dominant
physician specialty, health plan location and baseline
costs. After 1 :1 matching, 12 months of follow-up cost
and utilization data were then compared using
unmatched t-tests.
RESULTS: Of 11,443 patients, 3,341 (29.2%) had at
least one prescription for lispro insulin, while the remain-
ing 8,102 (70.8%) had at least one regular (non-lispro)
insulin prescription. At baseline, lispro patients tended to
be younger, were more often Type 1 with a history of
insulin use, had fewer comorbidities, visited endocrinol-
ogists over family practice physicians and had lower total
costs. PS balancing assured that only the 1,832 most
appropriate patients of each type were then used in out-
comes comparisons. Lispro patients had signiﬁcantly
higher average ofﬁce visits (p = 0.0022) and pharmacy
prescriptions (p = 0.0165) but lower inpatient hospital
visits (p = 0.0028) compared to non-lispro patients. Cost
results were similar with lispro insulin patients having sig-
niﬁcantly higher average ofﬁce visit costs (p = 0.0237) and
pharmacy costs (p < 0.0001) but lower inpatient hospital
costs (p = 0.0227). Total costs were not signiﬁcantly 
different (p = 0.5266).
CONCLUSIONS: Lispro insulin and non-lispro regular
insulin patients did not incur signiﬁcantly different total
costs. While lispro patients had higher pharmacy and
ofﬁce visit costs, they did not incur higher total medical
costs. More intensive ambulatory care in such chronic
disease patients does not appear to be associated with
higher overall medical costs.
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FACTORS PREDICTING SELF-RATED HEALTH
AND PATIENT SATISFACTION IN A MANAGED
CARE DIABETES POPULATION
Nau DP, Kumar RN
University of Michigan, Ann Arbor, MI, USA
OBJECTIVES: To determine the relationship of demo-
graphics, severity of illness and quality of care measures
with general health perception (GHP) and patient satis-
faction (PS) levels among managed care diabetes patients.
METHODS: The sample included 300 adult diabetes
patients enrolled in an IPA-model HMO. All data were
collected through surveys and medical claims. Survey data
from July 1999 were merged with medical and pharmacy
claims data from July 1998 through June 1999. Our
analysis consisted of two multiple regression models with
GHP (100 point transformed scale, higher score = better
health) and PS (9 point scale, higher score = greater sat-
isfaction) being the dependent variables, respectively. Pre-
dictor variables in both models included: demographics
(age, gender, education, income), severity of illness
(insulin use, duration of diabetes), number of comorbidi-
ties, receipt of foot and eye exams, diabetes education,
lipid tests, microalbumin tests, frequency of self-
monitoring of blood glucose, and the frequency of tests
for HbA1c and blood glucose.
RESULTS: Mean (SD) for GHP and PS scores were 49.8
(25.0) and 7.8 (1.8), respectively. The R2 for model 1
(GHP) and model 2 (PS) were 0.20 and 0.10, respectively.
Signiﬁcant predictors (p < 0.05) of GHP included comor-
bidities (beta = -0.11), income (beta = 0.26), and HbA1c
tests (beta = 0.19). Thus, higher GHP was associated with
having fewer comorbidities, higher income and more fre-
quent testing of HbA1c in the prior year. Signiﬁcant pre-
dictors of PS included comorbidities (beta = -0.15), foot
exams (beta = 0.16), and diabetes education (beta = 0.16).
Thus, higher satisfaction was associated with fewer
comorbidities, receipt of a foot exam from any healthcare
provider, and participation in a diabetes education
program.
CONCLUSION: When controlling for demographics,
comorbidities and severity of illness, those patients who
received more frequent HbA1c monitoring reported
higher self-rated health, and patients who received foot
exams and diabetes education were more satisﬁed with
the care they received for diabetes.
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TREATMENT OF TYPE-2 DIABETES MELLITUS
Conklin JE1, Neslusan CA2, Cohen F3, Song X1
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2Pharmaceuticals Group Strategic Marketing, Raritan, NJ, USA;
3RW Johnson Pharmaceutical Research Institute, Raritan, NJ,
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OBJECTIVES: New oral antihyperglycemic drugs
(OADs) have been introduced in recent years, and dia-
betes treatment guidelines are increasingly suggesting that
insulin be used for type-2 diabetes only when other ther-
apies are ineffective. This study evaluates the resulting
impacts on trends in insulin mono and combination 
therapies for type-2 diabetic patients from 1997–2000.
METHODS: Commercially insured patients who had one
or more diabetes diagnoses or drugs are selected from
over 3 million employees, retirees, and dependents in each
of the years 1997–2000 of The MEDSTAT Group Mar-
ketScan database. Patients likely to have type-1 diabetes
are identiﬁed and removed from the database. Descrip-
tive analyses compare the percentages of type-2 diabetes
patients treated with insulin monotherapy and speciﬁc
combination therapies in each of the four years. Statisti-
